Investment Rating - The industry investment rating is maintained at "Overweight" [2][9]. Core Insights - The vaccine industry is experiencing a transition from scale expansion to innovation-driven growth, with short-term pain due to supply-demand imbalance and homogenized competition, but the long-term positive outlook remains unchanged [9][27]. - Recent advancements in vaccine technology and policy changes are expected to drive demand, particularly with the expansion of the immunization program for Japanese encephalitis vaccines in certain regions [4][9]. - Companies like Zhifei Biological are making significant progress with new vaccine candidates, including an mRNA vaccine for shingles and a lyophilized inactivated vaccine for chickenpox, which could enhance their competitive edge [4][9]. Summary by Sections Industry Performance - The vaccine sector has seen a cumulative decline of 11.36% since 2025, with a recent weekly drop of 1.42% [5][11]. - Relative performance against the CSI 300 index shows a decline of 29% over the past 12 months [4]. Company Developments - Zhifei Biological has received clinical trial approval for two new vaccines, indicating progress in both mRNA and inactivated vaccine technologies [4]. - The company is focusing on innovative vaccine development to enhance its product pipeline and market competitiveness [9]. Market Dynamics - The vaccine industry is currently facing challenges such as high competition among Me-too products and a decline in demand due to consumer hesitancy [8][24]. - The industry is expected to adjust its pipeline strategies, emphasizing innovation and multi-valent products to improve market positioning [8][24]. Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio is reported at 65.37X, with a recent decrease of 1.47X, while the price-to-book (PB) ratio stands at 1.21X [7][19]. - The PE ratio is at the 55.06% percentile since 2013, indicating a relatively high valuation compared to historical data [7]. Investment Recommendations - The report suggests focusing on companies with strong research and innovation capabilities, particularly those with differentiated product offerings, such as CanSino [9][27]. - Long-term investment opportunities are anticipated in the context of innovation and international market expansion [8][9].

Core Viewpoint - The company, Zhifei Biological Products (300122), has received clinical trial approval for two vaccines developed by its wholly-owned subsidiary, Zhifei Longkema, indicating a continuous expansion of its vaccine research pipeline [1] Group 1: Vaccine Approvals - On February 3, the company announced the approval of its mRNA vaccine for shingles, which is a product based on its proprietary mRNA technology, marking the first mRNA vaccine approved for clinical trials in China [1] - The shingles mRNA vaccine is noted for its good immunogenicity and high safety profile, effectively preventing the occurrence of shingles [1] - On February 4, the company announced the approval of its lyophilized inactivated varicella vaccine, which utilizes an innovative inactivation technology and is suitable for individuals aged 12 months and older [1] Group 2: Safety and Target Population - The varicella vaccine is designed to provide a safer option for both healthy individuals and those with immune deficiencies or contraindications for vaccination [1] - The company emphasizes that vaccine development involves significant investment, long cycles, and high risks, with uncertainties regarding the clinical trial progress, results, and subsequent approval for production and commercialization [1] Group 3: Financial Impact - The company indicates that the clinical trials for the two vaccines will not have a significant impact on its recent financial performance and will continue to fulfill its information disclosure obligations as required [1]

Policy Developments - Shanghai aims to vigorously cultivate and develop future industries such as brain-computer interfaces and fourth-generation semiconductors, as stated in the government work report presented at the Shanghai Municipal People's Congress [1] Drug and Medical Device Approvals - Novartis announced that its innovative biological drug Cosentyx (secukinumab) has received approval from the National Medical Products Administration in China for a new indication to treat active non-radiographic axial spondyloarthritis in adults who have had an inadequate response to non-steroidal anti-inflammatory drugs [2] - Hualan Biological announced that its recombinant Exendin-4-Fc fusion protein injection (HL08) has received clinical trial approval for use in adult patients with obesity or overweight, expanding its indications beyond type 2 diabetes [3] - Bibet's BEBT-701, a globally first AGT/PCSK9 dual-target siRNA drug, has received approval for clinical trials to treat mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol [4] - Zhifei Biological's mRNA vaccine for shingles has received clinical trial approval from the National Medical Products Administration [5] Financial Data - Yaokang Biological reported a total revenue of 793 million yuan for 2025, a year-on-year increase of 15.49%, and a net profit of 144 million yuan, reflecting a growth of 31.49% [6] Industry Developments - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization rights agreement for the Inusimab injection, paying an authorization fee of 80 million yuan [7][8] - Insilico Medicine announced it received a milestone payment of 39 million HKD from Menarini after the MEN2501 project completed its first patient dosing in Phase I clinical trials [9] - WuXi Biologics has signed a licensing and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T cell engager, which will be used to treat B cell-mediated autoimmune diseases [10]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

Core Viewpoint - The company announced that its subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of its shingles mRNA vaccine, which is aimed at preventing shingles [1] Group 1 - The approval of the shingles mRNA vaccine clinical trial is not expected to have a significant impact on the company's recent performance [1] - This project will help the company strengthen its research and development capabilities and enhance its pipeline reserves [1] - There is uncertainty regarding the subsequent clinical trial progress, results, and product launch, and the company will fulfill its information disclosure obligations based on R&D progress [1]

Core Viewpoint - Zhifei Biological (300122.SZ) has received approval from the National Medical Products Administration for clinical trials of its mRNA vaccine for shingles, developed by its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd [1] Group 1 - The mRNA vaccine is specifically aimed at preventing shingles [1] - The approval notification number for the clinical trial is 2026LP00326 [1]

Core Viewpoint - The company Zhifei Biological Products Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its mRNA vaccine aimed at preventing shingles [1] Group 1 - The subsidiary Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. is responsible for the development of the shingles mRNA vaccine [1] - The approval allows the company to proceed with clinical trials for the vaccine [1]

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary, Zhifei Longkema, has received approval from the National Medical Products Administration for clinical trials of an mRNA vaccine aimed at preventing shingles, which enhances the company's product portfolio and market position [2] Group 1 - Zhifei Biological's mRNA vaccine for shingles has been granted clinical trial approval [2] - The vaccine is developed using the company's proprietary mRNA technology, demonstrating good immunogenicity and safety [2] - This approval will enrich the company's adult vaccine offerings and strengthen its market position [2]

Core Viewpoint - The company is actively developing multiple vaccine technology platforms, including mRNA and novel adjuvant technologies, to achieve innovation and upgrades in vaccine products [2] Group 1 - The company has established an mRNA technology platform and a novel adjuvant technology platform [2] - The company’s subsidiary, Zhifei Longkema, has received a clinical trial acceptance notice from the National Medical Products Administration for its shingles mRNA vaccine [2] - The company aims to explore various vaccine development pathways for iterative upgrades and breakthroughs in vaccine products [2]

Core Viewpoint - The company has developed an mRNA vaccine for shingles, which has received acceptance for clinical trial application from the National Medical Products Administration [1] Group 1 - The company's wholly-owned subsidiary, Zhifei Longkema, is responsible for the research and development of the shingles mRNA vaccine [1] - The clinical trial application for the shingles mRNA vaccine has been officially accepted, indicating progress in the vaccine's development [1]